JAKi、TNFi与非TNFi bDMARDs治疗类风湿关节炎与首次及第二原发角质细胞癌风险:瑞典全国性研究
该瑞典全国性队列研究纳入21756例类风湿关节炎患者,评估JAKi、TNFi与非TNFi bDMARDs治疗与首次及第二原发角质细胞癌(KC)风险的关系。
要点
- JAKi与基底细胞癌(HR 1.41)及鳞状细胞癌(HR 1.49)风险升高相关。
核心结论
- JAKi治疗类风湿关节炎患者的角质细胞癌风险高于TNFi治疗者。
- 非TNFi bDMARDs整体不增加KC风险,但阿巴西普重复出现鳞状细胞癌风险升高的药物特异性信号。
- 第二原发KC风险在JAKi与非TNFi bDMARDs中均未见显著升高。
研究设计与样本
- 瑞典全国性队列研究,使用瑞典风湿病质量登记链接包括国家癌症登记在内的其他登记数据,2012年至2023年。
- 纳入接受JAKi、TNFi或非TNFi bDMARDs治疗的类风湿关节炎患者,共识别21756例唯一患者。
- 采用Cox回归估计调整风险比(HR),以TNFi为参照。
临床怎么用
- 对接受JAKi治疗的类风湿关节炎患者,应关注角质细胞癌风险,尤其是基底细胞癌和鳞状细胞癌。
- 使用阿巴西普的患者需注意鳞状细胞癌风险信号。
- 非TNFi bDMARDs整体不增加KC风险,但需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to assess the risks of primary and second primary keratinocyte cancers (KCs) in patients with rheumatoid arthritis (RA) and in relation to treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs. METHODS: Nationwide cohort study of patients treated with Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitor (TNFi), or non-TNFi bDMARDs, using data from the Swedish Rheumatology Quality Register linked to other registers including the National Cancer Register, 2012 through 2023. Adjusted hazard ratios (HRs) were estimated via Cox regression using TNFi as reference. RESULTS: We identified 21,756 unique patients with RA. Based on 155 incident KC with JAKi, 458 with non-TNFi and 766 with TNFi, the HR for JAKi vs TNFi was 1.39 (1.16-1.68), corresponding to 1 extra KC case per every 244 patients per year. For non-TNFi vs TNFi, the HR was 0.96 (0.86-1.08). By subtype, the HR for JAKi vs TNFi was 1.41 (1.13-1.75) for basal cell carcinoma and 1.49 (1.09-2.05) for squamous cell carcinoma (SCC). For abatacept vs etanercept, the HR for SCC was 1.48 (1.11-1.97). The HR for a second primary KC was 1.31 (0.94-1.82) for JAKi and 0.94 (0.75-1.17) for non-TNFi bDMARD vs TNFi. CONCLUSIONS: Patients treated with JAKi have an elevated risk of KC compared with patients treated with TNFi. Although the class of non-TNFi bDMARDs is not associated with increased KC risk, we repeated a drug-specific signal of increased risk for SCC with abatacept.
引用
- Huss V, Bower H, Björklund M, et al. Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide study. Ann Rheum Dis. 2026. PMID: 41826213. doi:10.1016/j.ard.2026.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。